LDL-C THERAPEUTIC TARGET ATTAINMENT IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE

被引：0
|
作者：
Underberg, James [1 ]
Harada-Shiba, Mariko [2 ]
Hegele, Robert A. [3 ]
McCullough, Peter A. [4 ]
DiGioia, Kenneth [5 ]
Jurecka, Agnieszka [5 ]
Stefanutti, Claudia [6 ]
Blom, Dirk [7 ]
机构：
[1] NYU, Ctr Prevent Cardiovasc Dis, New York, NY USA
[2] Natl Cerebral & Cardiovasc Ctr, Res Inst, Osaka, Japan
[3] Robarts Res Inst, London, ON, Canada
[4] Baylor Univ, Med Ctr, Dallas, TX USA
[5] Aeger Pharmaceut, Cambridge, MA USA
[6] Sapienza Univ Rome, Rome, Italy
[7] Univ Cape Town, Cape Town, South Africa
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2018年 / 32卷
关键词：
D O I：
10.1016/j.atherosclerosissup.2018.04.468
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
P5.046
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [41] Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels * , **
    Bianconi, Vanessa
    Banach, Maciej
    Pirro, Matteo
    TRENDS IN CARDIOVASCULAR MEDICINE, 2021, 31 (04) : 205 - 215
  • [42] THE HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN A POPULATION OF ASCVD PATIENTS WITH LDL-C ABOVE TARGET: AN ANALYSIS FROM THE REACT REGISTRY
    Gupta, Milan
    Zawadka, Magdaline
    Aljenedil, Sumaia
    Kajil, Mahesh
    Bewick, David
    Gaudet, Daniel
    Hegele, Robert
    Lonn, Eva
    Ngui, Daniel
    Alothman, Latifah
    Ruel, Isabelle
    Singh, Narendra
    Genest, Jacques
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 90 - 90
  • [43] Gemcabene and Atorvastatin Alone and Combined Markedly Reduce LDL-C in LDL Receptor-deficient Mice, a Model of Homozygous Familial Hypercholesterolemia
    Bisgaier, Charles L.
    Auerbach, Bruce J.
    CIRCULATION, 2015, 132
  • [44] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis (vol 41, pg 837, 2024)
    Alshahrani, Awad
    Kholaif, Naji
    Al-Khnifsawi, Mutaz
    Zarif, Hawazen
    Mahzari, Moeber
    ADVANCES IN THERAPY, 2024, 41 (05) : 2083 - 2083
  • [45] MODELING THE POPULATION HEALTH BENEFITS OF LDL-C REDUCTION WITH ALIROCUMAB AMONG CARDIOVASCULAR DISEASE/HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LDL-C
    Sanchez, R.
    Nasir, K.
    Klimchak, A.
    Kuznik, A.
    Joulain, F.
    Briggs, A.
    ATHEROSCLEROSIS, 2018, 275 : E100 - E100
  • [46] CUMULATIVE LDL-C BURDEN AS A CVD RISK PREDICTOR ON FAMILIAL HYPERCHOLESTEROLEMIA
    Ressia, A.
    Dell'Oca, N.
    Reyes, X.
    Fernandez, G.
    Stoll, M.
    ATHEROSCLEROSIS, 2018, 275 : E81 - E82
  • [47] Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia
    Futema, Marta
    Bourbon, Mafalda
    Williams, Maggie
    Humphries, Steve E.
    ATHEROSCLEROSIS, 2018, 277 : 457 - 463
  • [48] Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia
    Gouni-Berthold, Ioanna
    Berthold, Heiner K.
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 28 - 34
  • [49] Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
    Claudia Stefanutti
    Current Atherosclerosis Reports, 2020, 22
  • [50] Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice
    Gandhi, Sanjay K.
    Jarbrink, Krister
    Fox, Kathleen M.
    Brandrup-Wognsen, Gunnar
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2817 - 2828
12345